By Aman Jandu 
Discover what healthcare professionals (eHCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are eHCPs responding to drug launch news? How are eHCPs talking about or engaging with the Top 50 pharma companies on social media? Each week, CREATION.co’s tracking updates bring you the latest insights from the conversation of eHCPs across the globe discussing these topics and more.
The Top 50 Pharmaceutical Companies mentioned by eHCPs on X
| November Rank | October Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 1 | Pfizer | 4,232 | 529 | 8 |
| 2 | 2 | Moderna | 2,689 | 120 | 0 |
| 3 | 5 | AstraZeneca | 793 | 317 | 10 |
| 4 | 4 | Johnson & Johnson | 728 | 290 | 21 |
| 5 | 6 | GSK | 581 | 183 | 41 |
| 6 | 7 | Novo Nordisk | 390 | 252 | 11 |
| 7 | 13 | Bayer | 384 | 106 | 17 |
| 8 | 16 | Lilly | 383 | 289 | 0 |
| 9 | 3 | Novavax | 373 | 67 | 5 |
| 10 | 15 | Abbott | 250 | 235 | 3 |
| 11 | 12 | Roche | 236 | 84 | 21 |
| 12 | 10 | Sanofi | 233 | 102 | 24 |
| 13 | 38 | Vertex | 212 | 212 | 4 |
| 14 | 9 | Gilead Sciences | 206 | 83 | 1 |
| 15 | 11 | Novartis | 205 | 110 | 12 |
| 16 | 8 | BioNTech | 176 | 17 | 0 |
| 17 | 18 | AbbVie | 140 | 110 | 19 |
| 18 | 19 | Amgen | 117 | 84 | 2 |
| 19 | 20 | Takeda | 115 | 107 | 0 |
| 20 | 14 | Merck & Co | 98 | 66 | 16 |
| 21 | 17 | BMS | 94 | 74 | 1 |
| 22 | 35 | Viatris | 63 | 1 | 0 |
| 23 | 29 | Otsuka | 61 | 11 | 0 |
| 24 | 21 | Boehringer Ingelheim | 57 | 43 | 1 |
| 25 | 27 | Organon | 48 | 1 | 0 |
| 26 | 23 | Regeneron | 43 | 18 | 2 |
| 27 | 22 | Fresenius | 41 | 24 | 8 |
| 28 | 33 | UCB | 36 | 29 | 9 |
| 29 | 25 | Daiichi Sankyo | 35 | 17 | 1 |
| 30 | 32 | Astellas | 33 | 26 | 0 |
| 31 | 37 | Ipsen | 26 | 18 | 0 |
| 32 | 31 | Teva | 24 | 19 | 1 |
| 33 | 26 | Eisai | 20 | 8 | 1 |
| 33 | 28 | Merck KGaA | 20 | 19 | 1 |
| 35 | 30 | Servier | 19 | 8 | 7 |
| 36 | 39 | Grifols | 18 | 5 | 0 |
| 37 | 36 | Bausch | 16 | 5 | 0 |
| 38 | 43 | Incyte | 15 | 13 | 0 |
| 39 | 34 | Biogen | 10 | 6 | 1 |
| 40 | 40 | Menarini | 8 | 5 | 0 |
| 41 | 24 | CSL | 7 | 7 | 1 |
| 42 | 41 | Chugai | 5 | 3 | 3 |
| 42 | 44 | Horizon | 5 | 5 | 0 |
| 44 | 42 | Jazz Pharmaceuticals | 4 | 2 | 0 |
| 45 | 50 | Perrigo | 2 | 1 | 0 |
| 50 | 45 | CSPC | 0 | 0 | 0 |
| 50 | 46 | Sun | 0 | 0 | 0 |
| 50 | 50 | Sino | 0 | 0 | 0 |
| 50 | 50 | Shanghai | 0 | 0 | 0 |
| 50 | 50 | Jiangsu Hengrui | 0 | 0 | 0 |
The latest insights from eHCPs mentioning the Top 50 Pharmaceutical Companies
The five pharmaceutical companies that were mentioned the most by eHCPs on X in November 2023 were Pfizer, Moderna, AstraZeneca, Johnson & Johnson, and GSK.
CREATION.co identified 11,169 eHCP mentions of pharmaceutical companies in November 2023, decreasing by 13% over the previous month.
On 08 November, Eli Lilly announced it had received FDA approval for the chronic weight management drug, “Zepbound”. eHCPs took the opportunity to share the news with their peers – calling the drug “remarkable”.
“Zepbound”
Get used to saying that 😊
“Shedding a quarter of your body weight”… remarkable new Rx option
FDA approves new obesity drug from Eli Lilly named Zepbound – The Washington Post https://t.co/goa4Sz12MK
— Sek Kathiresan MD (@skathire) November 9, 2023
Clinician Scientist Daniel J. Drucker shared the news, describing it as “the most effective GLP-1 based medicine to date”.
The most effective GLP-1-based medicine to date, Tirzepatide, approved by @US_FDA for treatment of people living with #obesity and weight management, marketed as Zepbound, by @EliLillyandCo 2.5-15mg doses, 20% less expensive than 2.4 semaglutide ow https://t.co/cvjjD8WuT4
— Daniel J Drucker (@DanielJDrucker) November 8, 2023
Abbott hosted a series of cardiology training sessions this month, following their sessions delivered in October. On 20 November, cardiologist Ian McLeod shared a short overview of the event, sharing how he “really enjoyed” partnering with Abbott in the delivery of the sessions.
Really enjoying being partners with @AbbottGlobal to provide amazing tutorial sessions at #PCRLV – @GeHealthcare #Echofirst #Cardiotwitter #GEVIVID #GEHealthcare pic.twitter.com/iYfBJiS08A
— Ian Mcleod (@GE_IanMc) November 20, 2023
The top shared links by eHCPs when mentioning a Top 50 pharma company discussed:
- A press release from Eli Lilly sharing the FDA approval of Zepbound.
- A Nobel Prize article honouring Katalin Karikó and Drew Weissman for their discoveries, enabling the development of mRNA COVID-19 vaccines.
- A poster by ASE for Cardiac Amyloidosis, developed in collaboration with Pfizer.
CREATION.co continues to analyse online eHCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
Methodology notes:
- In November 2023, CREATION Pinpoint® identified 11,169 healthcare professional authored posts on X (Twitter) from 3,965 individual eHCPs mentioning a Top 50 Pharmaceutical company (according to revenue).
- Data for this research was analysed from the online X conversations of eHCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 – 30 November 2023.
- Unless otherwise specified, mentions of a company are not limited to its X account(s).
- In some cases, an X post may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Johnson & Johnson Innovative Medicine (previously Janssen). In November 2023, 56 of these posts mentioned Johnson & Johnson Innovative Medicine or Janssen.
Top 50: https://creation.co/resources/hcp-insight-trackers/top-50-pharma-tracker/
Product approval: https://creation.co/resources/hcp-insight-trackers/product-launch-tracker/
All trackers: https://creation.co/resources/hcp-insight-trackers/
